| Description |
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC50 <100 nM in a TR-FRET assay).
|
| Related Catalog |
|
| Target |
IC50: < 100 nM (BET in a TR-FRET assay)[1].
|
| In Vitro |
BAY 1238097 shows strong inhibitory activity (IC50 < 100 nM) in a TR-FRET assay using BET BRD4 bromodomain 1 and an acetylated peptide derived from histone H4. In the NanoBRET assay, the interaction between BRD4 (IC50=63 nM), BRD3 or BRD2 (IC50=609 nM) and H4 (IC50=2430 nM) is inhibited[1]. BAY 1238097 has in vitro anti-tumour activity in lymphoma models. BAY 1238097 affects the gene expression of GCB DLBCL cells. At the gene level, 143 probes (121 annotated transcripts) are downregulated and 71 (59 annotated transcripts) are upregulated. BTK, CCDC86, CCND2, CD19, CD27, FAIM, FCMR (FAIM3), IL7R, IRAK1, MAPK13, MYB, MYC, PDE4B, TNFRSF13B, TNFRSF17 are among the top downregulated genes. Beside histone-coding genes, the upregulated genes include CCL5, CDKN2C, CD69, JUN, and MKNK2[2].
|
| In Vivo |
BAY 1238097 shows strong efficacy in the AML models THP-1, MOLM-13 and KG-1, with T/C between 13 and 20%. BAY 1238097 is also active in MM models in a human IGH-cyclin D1 translocated MOLP-8 model with a T/C of 3%. In this model, BAY 1238097 is well tolerated at 10 mg/kg applied over 14 days, with no body weight loss measured. BAY 1238097 is also active against the FGFR/MMSET translocated model NCIH929, with 19% T/C versus 49% T/C for the standard-of-care lenalidomide. BAY 1238097 is well tolerated applied at 12 mg/kg for 9 days (maximum body weight loss 6%)[1]. BAY 1238097 has in vivo anti-tumour activity in lymphoma models[2].
|
| Animal Admin |
Mice[2] Severe combined immunodeficiency (SCID) female mice (9-12 weeks old) are inoculated subcutaneously into the right flank with 5×106 SU-DHL-8 cells/mouse suspended in 0.1 mL of matrigel or with OCI-LY-3 tumour fragments (3×3 mm). BAY 1238097 is administered orally at 10 mL/kg. Treatments with BAY 1238097 or vehicle control are initiated on day 4 post tumour inoculation for the SU-DHL-8 model (8 mice/group). BAY 1238097 is applied daily for 12 days at its maximal tolerated dose (MTD) of 15 mg/kg. Treatment of the OCI-LY-3 tumours start on day 21 post-tumour inoculation, with mice being randomized with a median tumour size per group of 98 mm3 for the BAY 1238097-treated group (n=7) and 93 mm3 for the vehicle control group (n=8). BAY 1238097 is applied at the MTD of 45 mg/kg using an intermittent schedule, twice a week, for 4 weeks[2].
|
| References |
[1]. Lejeune, P., et al. (2015) Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 75(15 Suppl), 884. [2]. Bernasconi E, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948.
|
